Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 809,102 | 648,719 | 535,608 | 230,276 | 483,610 |
| Marketable Securities | 236,121 | 251,761 | 158,376 | 77,819 | 43,332 |
| Receivables | 1,467,793 | 976,372 | 954,967 | 693,120 | 103,035 |
| Inventories | 238,578 | 128,861 | 70,354 | 28,638 | N/A |
| Income taxes - deferred | N/A | N/A | 44,677 | 148,134 | 0 |
| TOTAL | $2,915,095 | $2,084,759 | $1,796,934 | $1,206,012 | $665,777 |
| Non-Current Assets | |||||
| PPE Net | 1,594,120 | 974,309 | 526,983 | 379,940 | 367,955 |
| Investments And Advances | 632,162 | 460,154 | 389,891 | 271,230 | 275,887 |
| Other Non-Current Assets | 467,755 | 318,450 | 237,205 | 223,308 | 13,964 |
| TOTAL | $2,694,037 | $1,752,913 | $1,154,079 | $874,478 | $657,806 |
| Total Assets | $5,609,132 | $3,837,672 | $2,951,013 | $2,080,490 | $1,323,583 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 644,112 | 483,489 | 250,896 | 111,345 | 95,625 |
| Other current liabilities | 13,563 | 97,146 | 939 | N/A | N/A |
| TOTAL | $811,162 | $654,660 | $298,835 | $163,550 | $148,271 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 153,487 | 74,025 | 47,000 | 50,831 | 51,640 |
| Other Non-Current Liabilities | 115,535 | 186,574 | 331,645 | 303,777 | 281,462 |
| TOTAL | $1,143,133 | $632,761 | $700,102 | $671,555 | $689,580 |
| Total Liabilities | $1,954,295 | $1,287,421 | $998,937 | $835,105 | $837,851 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 104,788 | 102,617 | 99,928 | 97,451 | 93,889 |
| Common Shares | 108 | 104 | 99 | 97 | 93 |
| Retained earnings | 852,700 | 216,644 | -92,692 | -517,054 | -1,267,323 |
| Other shareholders' equity | 8,503 | 52,721 | -1,188 | -1,166 | -1,862 |
| TOTAL | $3,654,837 | $2,550,251 | $1,952,076 | $1,245,385 | $485,732 |
| Total Liabilities And Equity | $5,609,132 | $3,837,672 | $2,951,013 | $2,080,490 | $1,323,583 |